Q2 EPS Forecast for Harmony Biosciences Boosted by Analyst

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Investment analysts at HC Wainwright increased their Q2 2026 earnings estimates for Harmony Biosciences in a report issued on Monday, July 20th. HC Wainwright analyst P. Trucchio now expects that the company will earn $1.11 per share for the quarter, up from their prior estimate of $0.68. HC Wainwright currently has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.26 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q3 2026 earnings at $1.00 EPS and FY2026 earnings at $3.54 EPS.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Thursday, May 7th. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.21). Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The firm had revenue of $215.39 million during the quarter, compared to analyst estimates of $220.84 million. During the same period last year, the business earned $0.78 EPS. The firm’s revenue was up 16.6% compared to the same quarter last year.

Several other research analysts have also recently issued reports on the company. Weiss Ratings raised Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, June 23rd. Truist Financial boosted their target price on Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a research note on Friday, May 8th. Zacks Research raised Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on shares of Harmony Biosciences from $30.00 to $36.00 and gave the company a “hold” rating in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Harmony Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $42.50.

Harmony Biosciences Stock Up 10.0%

Harmony Biosciences stock opened at $36.84 on Wednesday. The stock has a market cap of $2.13 billion, a PE ratio of 14.85, a P/E/G ratio of 0.32 and a beta of 0.94. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.58 and a quick ratio of 3.56. The stock’s fifty day moving average is $33.66 and its two-hundred day moving average is $32.64. Harmony Biosciences has a 1-year low of $25.52 and a 1-year high of $40.87.

Institutional Trading of Harmony Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC lifted its holdings in shares of Harmony Biosciences by 109.9% in the 1st quarter. SG Americas Securities LLC now owns 2,018,174 shares of the company’s stock valued at $56,529,000 after purchasing an additional 1,056,507 shares during the last quarter. Armistice Capital LLC purchased a new position in Harmony Biosciences during the 4th quarter worth approximately $18,710,000. AQR Capital Management LLC increased its holdings in shares of Harmony Biosciences by 128.9% in the 4th quarter. AQR Capital Management LLC now owns 813,889 shares of the company’s stock valued at $30,456,000 after acquiring an additional 458,321 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in shares of Harmony Biosciences by 42.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,295,381 shares of the company’s stock valued at $35,701,000 after acquiring an additional 388,472 shares during the period. Finally, UBS Group AG raised its position in Harmony Biosciences by 213.3% in the 3rd quarter. UBS Group AG now owns 503,081 shares of the company’s stock valued at $13,865,000 after purchasing an additional 342,505 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.